Apollo LX Launch Success -- one giant leap for global Pharma & Biotech

Jan 05, 2016, 01:00 ET from GalbraithWight

PRINCETON, N.J., Jan. 5, 2016 /PRNewswire/ -- GalbraithWight, a global market access consultancy, announces the launch of Apollo LX, the first & only global Launch Excellence planning application with GalbraithWight's Market Access and Launch Planning expertise embedded in its platform.

72% of new medicines are a commercial 'flop'1 & a row of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly tough Payer reimbursement environment2.

According to CEO & market access expert, Colin Wight, "Outside of product failure, major reasons for launch failure include planning too late, lack of communication between functions & between HQ & country teams & worst of all, failure to address the vital Payer requirements for market access early enough, resulting in a last minute scramble to fix something that could have been foreseen."

It costs $2.5 billion to develop a new medicine3, so it makes sense to ensure every launch has the best possible chance of success, more patients get access to life saving or life enhancing medicines they deserve, & investors get the returns they are expecting.

That is why GalbraithWight has launched Apollo LX.

Apollo LX is specifically designed for pharmaceutical & biotech launch planning, and comes fully loaded with GalbraithWight's global market access & launch planning framework – everything you need to develop & implement a highly successful launch.

Apollo LX is an easy-to-use web application that provides global visibility and control of brand launches across the enterprise to improve communication between functions and between HQ & countries.

Apollo LX provides launch planning, communication & tracking, with ultimate user ease, clarity and control to create launch success, so with Apollo LX, launch excellence can now be a reality.

See more about Apollo LX at www.apollolx.com

About GalbraithWight:
A global market access consultancy with almost 20 years successful Consulting & Training experience, a team of expert Consultants with extensive senior level international strategic & operational experience, plus proven capability delivering solutions on the ground throughout North & South America, Europe, Asia Pacific & the Middle East & Africa. GalbraithWight has worked on many major brands, including Yervoy, Lenvima, Opdivo, Ibrance, Eliquis, Gardasil, Forxiga, Empliciti, Sivextro, Zerbaxa and many others. GalbraithWight has offices in Princeton, NJ & Milan, Italy.


1. http://www.simon-kucher.com/en-us/news/72-percent-all-new-products-flop 
2. http://www.nature.com/nbt/journal/v31/n1/full/nbt.2482.html 
3. http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014..pdf 

Logo - http://photos.prnewswire.com/prnh/20160104/318927LOGO
Logo - http://photos.prnewswire.com/prnh/20160104/318970LOGO

SOURCE GalbraithWight